<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348918</url>
  </required_header>
  <id_info>
    <org_study_id>DME 202B</org_study_id>
    <nct_id>NCT02348918</nct_id>
  </id_info>
  <brief_title>A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema</brief_title>
  <official_title>A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allegro Ophthalmics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trial Runners, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Allegro Ophthalmics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical trial Designed to
      Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin®
      and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of Luminate® (ALG-1001) as compared to Avastin® and focal
      laser photocoagulation in patients with diabetic macular edema

      - 150 eligible subjects with DME will be enrolled and randomized to one of 5 treatment
      groups, i.e., one of three doses of Luminate intravitreal injection or Avastin intravitreal
      injection or focal laser photocoagulation. Subjects will be followed monthly for 24 weeks (6
      months)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in OCT (Optical coherence tomagraphy) Central Subfield Thickness at Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The primary efficacy outcome is OCT central subfield thickness at Week 24 as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA at Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Secondary efficacy outcome is BCVA changes at Week 24 as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Luminate 1.0mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luminate 2.0mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luminate 3.0mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin® group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required; sham laser treatment will be administered at baseline and at 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>focal laser photocoagulation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Focal laser photocoagulation performed at baseline (Day 0) with possible prn laser retreatment at week 16. Sham intravitreal injections will be performed at baseline (Day 0), 4 weeks, 8 weeks, 12 weeks, 16 weeks and 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luminate 1.0mg</intervention_name>
    <arm_group_label>Luminate 1.0mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luminate 2.0mg</intervention_name>
    <arm_group_label>Luminate 2.0mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luminate 3.0mg</intervention_name>
    <arm_group_label>Luminate 3.0mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <arm_group_label>Avastin® group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Focal laser photocoagulation</intervention_name>
    <arm_group_label>focal laser photocoagulation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older.

          2. Study eye with clinically significant diabetic macular edema (DME) with central
             subfield thickness ≥ 350µm on spectral domain OCT

          3. Best corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to
             23 letters) in the study eye, with BCVA decrement primarily attributable to DME.

          4. Treatment naïve, i.e., no previous anti-VEGF treatment in the study eye or no
             anti-VEGF treatment in the 45 days prior to study enrollment.

          5. In the investigator's opinion, the subject still has significant intraretinal fluid
             with room for improvement in both macular edema and BCVA.

          6. Intra-Ocular Pressure (IOP) is under control (i.e., IOP

             ≤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.

          7. Willing and able to return for all study visits.

          8. Able to meet the extensive post-op evaluation regimen.

          9. Understands and signs the informed consent form.

        Exclusion Criteria:

          1. Active proliferative diabetic retinopathy (PDR) in the study eye such as NVE, NVD,
             vitreous hemorrhage, or neovascular glaucoma.

          2. Uncontrolled hypertension defined as systolic &gt;180 mmHg or &gt; 160 mmHg on 2 consecutive
             measurements or diastolic &gt; 100 mmHg on optimal medical regimen

          3. Screening HgA1c blood test &gt; 10.0

          4. Focal laser photocoagulation or intravitreal/periocular steroids of any type in the
             study eye within the last 90 days prior to study enrollment.

          5. A history of intravitreal anti-VEGF injection of any type in the study eye within the
             last 45 days prior to study enrollment.

          6. History of rhegmatogenous retinal detachment, retinal tear(s), or traction retinal
             detachments in the study eye.

          7. Epiretinal membrane and/or vitreomacular traction in the study eye as determined by
             the central reading center.

          8. Previous pars plana vitrectomy in the study eye

          9. Any intraocular surgery in the study eye within the last 90 days prior to study
             enrollment.

         10. YAG laser treatment in the study eye in last 30 days prior to study enrollment.

         11. High myopia in the study eye, with a spherical equivalent of &gt;8.00D at screening

         12. Other ocular pathologies that in the investigator's opinion would interfere with the
             subject's vision in the study eye.

         13. Chronic or recurrent uveitis.

         14. Ongoing ocular infection or inflammation in either eye.

         15. A history of cataract surgery complications/vitreous loss in the study eye.

         16. Congenital eye malformations in the study eye.

         17. A history of penetrating ocular trauma in the study eye.

         18. Mentally handicapped.

         19. Pregnant female, as determined for women less than 60 years old by a positive urine
             pregnancy test during the screening window.

         20. Nursing female.

         21. Currently participating in any other clinical research study.

         22. Contraindication to the study medication. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicken Karageozian</last_name>
    <role>Study Director</role>
    <affiliation>Cheif Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hampar Karageozian</last_name>
    <phone>(949) 940 - 8130</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vicken Karageozian</last_name>
    <phone>(949) 940 - 8130</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Pheonix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwong, Dr.</last_name>
      <phone>602-216-1152</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Boyer, Dr.</last_name>
      <phone>310-854-6201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Palmer, Dr.</last_name>
      <phone>650-966-9307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Coast Retina</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arthur Fu, Dr.</last_name>
      <phone>415-975-0867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Medical Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanford Chen, Dr.</last_name>
      <phone>714-560-8401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nauman Chaudhry, Dr.</last_name>
      <phone>860-444-1827</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Eye Clinic</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Feldman, Dr.</last_name>
      <phone>407-834-7776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Gupta, Dr.</last_name>
      <phone>888-256-9591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Tolentino, Dr.</last_name>
      <phone>863-297-5400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute at John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Syed Shah, Dr.</last_name>
      <phone>410-955-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TLC Eye Group</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelina Gordon, Dr.</last_name>
      <phone>517-841-3034</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Island Retina</name>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Weber, Dr.</last_name>
      <phone>631-904-2415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlotte EENT Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Antoszyk, Dr.</last_name>
      <phone>704-295-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prema Abraham, Dr.</last_name>
      <phone>605-719-3280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wong, Dr.</last_name>
      <phone>512-451-0103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultant of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown, Dr.</last_name>
      <phone>800-833-5921</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wirthlin, Dr.</last_name>
      <phone>509-747-2635</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

